Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia

NCT02604433 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02604433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02604433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
May 2, 2016
Completion date
January 5, 2021
Enrollment
336 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, erythrocyte transfusion